Elron Announces that BrainsGate Notified the FDA of Its intention to Submit Its PMA Application During January 2020

Elron Announces Resolution to Renew D&O Liability Insurance Policy

Elron Announces that CEO Notified Board of Directors of Intention to Resign

Elron Announces Appointment of Eran Saar as Director

CartiHeal – Interim Results

Elron Announces that CartiHeal Completed Enrollment of Patients for Interim Analysis in FDA Pivotal Trial

Elron Announces Resignation of Sholem Lapidot as Alternate Director

Elron Announces that BrainsGate Submitted CE Mark Application for Marketing Approval in Europe

Elron Updates on Changes in Holdings of Interested Parties

Elron Announces Results of Public Offering

Elron Files Shelf Offering Report in Israel

Elron Announces Results of Tender to Qualified Investors for Early Commitments

Elron Announces Resolution to Increase Scope of D&O Liability Insurance Policy

Elron Announces It is Considering a Public Offering and Preparing to Conduct a Tender Offer to Qualified Investors

Elron Updates on Pocared’s Decision Not to Conduct a Clinical Trial at this Stage

Elron Announces Resignation of Benjamin Gantz as Director

Elron Announces Decision to Grant Directors’ Compensation to Controlling Persons

Elron Announces Filing of Shelf Prospectus in Israel

Elron Reports Option Grants